StreetInsider.com News Articles

Form 6-K Innate Pharma SA For: May 22

Fri, 22 May 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260522/26538153.html

Form 6-K Innate Pharma SA For: May 22

Fri, 22 May 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260522/26538153.html

Form 6-K Innate Pharma SA For: May 22

Fri, 22 May 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260522/26538153.html

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 21, 2026, in Marseille. All resolutions were voted.

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

Fri, 22 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

A total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.

The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026

Form 6-K Innate Pharma SA For: May 19

Tue, 19 May 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260519/26516625.html

Form 6-K Innate Pharma SA For: May 19

Tue, 19 May 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260519/26516625.html

Form 6-K Innate Pharma SA For: May 19

Tue, 19 May 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260519/26516625.html

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following conference:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma is advancing a portfolio of differentiated potential

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma is advancing a portfolio of differentiated potential

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma is advancing a portfolio of differentiated potential

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma is advancing a portfolio of differentiated potential

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma is advancing a portfolio of differentiated potential

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma is advancing a portfolio of differentiated potential

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma is advancing a portfolio of differentiated potential

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Tue, 19 May 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026
Location: New York, United States

About Innate Pharma

Innate Pharma is advancing a portfolio of differentiated potential